BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards
16 Dezember 2024 - 2:00PM
BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a
clinical-stage company advancing novel natural and engineered phage
therapies that target specific pathogenic bacteria, today announced
that it received written notification from the NYSE American LLC
(“NYSE American”), dated December 10, 2024, stating that the
Company has regained compliance with all NYSE American LLC
continued listing standards. Specifically, the Company has resolved
prior listing deficiencies raised on May 23, 2024, by NYSE American
and set forth in Sections 1003(a)(i), (ii) and (iii) of the
NYSE American Company Guide (the “Company Guide”). NYSE American
confirmed that the Company has demonstrated compliance with the
continued listing standard for a period of two consecutive quarters
pursuant to Section 1009(f) of the Company Guide.
About BiomXBiomX is a clinical-stage company
leading the development of natural and engineered phage cocktails
and personalized phage treatments designed to target and destroy
harmful bacteria for the treatment of chronic diseases with
substantial unmet needs. BiomX discovers and validates proprietary
bacterial targets and applies its BOLT (“BacteriOphage Lead to
Treatment”) platform to customize phage compositions against these
targets. For more information, please visit www.biomx.com, the
content of which does not form a part of this press release.
Safe HarborThis press release contains express
or implied “forward-looking statements” within the meaning of the
“safe harbor” provisions of the U.S. Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be identified by
words such as: “target,” “believe,” “expect,” “will,” “may,”
“anticipate,” “estimate,” “would,” “positioned,” “future,” and
other similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. For
example, the Company is making forward-looking statements when it
discusses its ability to continue to remain in compliance with NYSE
American listing standards. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead,
they are based only on BiomX management’s current beliefs,
expectations and assumptions. Because forward-looking statements
relate to the future, they are subject to inherent uncertainties,
risks and changes in circumstances that are difficult to predict
and many of which are outside of BiomX’s control. Therefore,
investors should not rely on any of these forward-looking
statements and should review the risks and uncertainties described
under the caption “Risk Factors” in BiomX’s Annual Report on Form
10-K filed with the Securities and Exchange Commission (the “SEC”)
on April 4, 2024, and additional disclosures BiomX makes in its
other filings with the SEC, which are available on the SEC’s
website at www.sec.gov. Forward-looking statements are made as
of the date of this press release, and except as provided by law
BiomX expressly disclaims any obligation or undertaking to update
forward-looking statements.
Contacts:BiomX, Inc.Ben
Cohenbenc@biomx.com
CORE IRPeter
Seltzbergir-biomx@biomx.com
BiomX (AMEX:PHGE)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
BiomX (AMEX:PHGE)
Historical Stock Chart
Von Dez 2023 bis Dez 2024